Navigation Links
Insmed to Present at 2011 Wedbush Securities Life Sciences Management Access Conference
Date:8/11/2011

MONMOUTH JUNCTION, N.J., Aug. 11, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that Timothy Whitten, President and CEO of Insmed, will be presenting a corporate overview at the 2011 Wedbush Securities Life Sciences Management Access Conference on Tuesday, August 16, 2011, at 8:00 AM ET, in New York.

A live audio webcast will be available on the Investors page of Insmed's website, http://www.insmed.com.  The webcast will also be archived for 90 days.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases, and has a proprietary protein platform aimed at niche markets with high unmet medical need. Insmed's primary focus is on the development of inhaled antibiotic therapy delivered via proprietary advanced pulmonary liposome technology in areas of high unmet need in lung diseases.  For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to our financial position, results of operations, the status and the results of preclinical studies and clinical trials and preclinical and clinical data described herein, the timing of responses to information and data requests from FDA, the development of our products, and the business strategies, plans and objectives of management, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements.  Our results may be affected by s
'/>"/>

SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Andrea Drucker Joins Insmed as General Counsel
2. Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication
3. Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
4. Insmed to Host Second Quarter 2009 Conference Call
5. Insmed Announces Addition to the Russell 3000(R) Index
6. Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
7. Insmed CEO Resigns Due to Health Concerns
8. Insmed Announces First Quarter 2009 Financial Results
9. Insmed Regains NASDAQ Compliance
10. Insmed to Host First Quarter 2009 Conference Call
11. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... a world-leading provider of scientific, technical and medical information ... recent study in Reproductive BioMedicine Online ... with an abnormal chromosomal composition can be identified by ... thereby classifying the risk of genetic abnormality without a ... undertaken a retrospective study, using their predictive model to ...
(Date:5/17/2013)... , May 17, 2013 ... by the most innovative thought leaders of the ... & Manufacturing East conference and expo, from June ...      (Photo: http://photos.prnewswire.com/prnh/20130517/613829 ) , ... designed to deliver industry professionals practical presentations and ...
(Date:5/17/2013)... JOSE, Calif. , May 17, 2013 /PRNewswire-iReach/ ... agreement has been reached with Switzerland ... portfolio of anti-infective human monoclonal antibody (mAb) products, ... anti-infective human mAb products for treatment of infections ... of Staphylococcus aureus , Pseudomonas aeruginosa ...
(Date:5/17/2013)... 2013 The paradigm of ‘one drug, ... that can help predict the adverse and therapeutic effects ... Head of Computational Biology at the Genomics Laboratory, Covance, ... ensure high-quality genomics when used as part of the ... complex data sets to identify key clinical targets even ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
... Close Completes $35 Million Financing, WOBURN, Mass., Nov. ... generation biologics for the treatment and,prevention of cancer and ... financing, concurrent with the completion of a,venture debt transaction, ... intends to use the capital to complete its preparations ...
... for,U-Md. Bioscience Day, COLLEGE PARK, Md., Nov. 14 ... technology enabling him to develop an,infinite variety of safe, ... capitalists and the title of "Best Inventor Pitch" at ... university,s Office of Technology Commercialization,the College of Chemical and ...
... Inc. (Nasdaq: ADLS ), a biopharmaceutical company ... drugs in the,therapeutic areas of infection, cancer and ... third quarter ended September 30,2007. (Logo: ... three months ended September 30, 2007 was $5.8,million ...
Cached Biology Technology:BioVex Closes Second Round of Series E Financing 2Pure Plastics Pitch Proves Perfect 2Pure Plastics Pitch Proves Perfect 3Advanced Life Sciences Announces Third Quarter 2007 Financial Results 2Advanced Life Sciences Announces Third Quarter 2007 Financial Results 3Advanced Life Sciences Announces Third Quarter 2007 Financial Results 4Advanced Life Sciences Announces Third Quarter 2007 Financial Results 5Advanced Life Sciences Announces Third Quarter 2007 Financial Results 6Advanced Life Sciences Announces Third Quarter 2007 Financial Results 7Advanced Life Sciences Announces Third Quarter 2007 Financial Results 8Advanced Life Sciences Announces Third Quarter 2007 Financial Results 9
(Date:5/16/2013)... Infections can trigger hematopoiesis at sites outside the bone ... skin.Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich now show that ... medullary" formation of blood cells. , Balanced hematopoiesis is ... fetal development, hematopoiesis takes place mainly in the liver ... the bone marrow, and this tissue normally serves as ...
(Date:5/16/2013)... the gym. But doctors use the human pulse as a ... professor of chemical engineering at Stanford, has developed a heart ... a postage stamp. The flexible skin-like monitor, worn under an ... doctors detect stiff arteries and cardiovascular problems. , The devices ... and provide doctors a safer method of measuring a key ...
(Date:5/15/2013)... that have powerful behavioral effects on diverse organisms ... ecosystems, according to a theory proposed in the ... of the theory, Ryan P. Ferrer of Seattle ... University of California at Los Angeles, liken such ... may be uncommon but exert a controlling influence, ...
Breaking Biology News(10 mins):Herpes infections: Natural killer cells activate hematopoiesis 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 3Natural 'keystone molecules' punch over their weight in ecosystems 2
... has chosen Springer to publish its official journal, ... be published at Springer in April 2009. The ... Science International focuses on the morphological sciences in ... and gross anatomical studies. In addition to original ...
... 16, 2009--Throughout the world, nitrogen compounds are released ... of fossil fuels. These pollutants are deposited to ... hundreds of miles downwind of their release point. ... a case in pointthough they contain little in ...
... Planting soybean on the optimum date produces maximum yield and ... is hard to indentify, because it varies from year to ... and when it rains. "Planting date has been ... into the United States, so there is a large database ...
Cached Biology News:Anatomical Science International joins Springer's publishing program 2Tree species composition influences nitrogen loss from forests 2No consistent advantage for planting soybean early 2
... Magnetofection technology, SilenceMag is the most ... rapid and easy to use, SilenceMag ... Specifically designed for siRNA delivery, SilenceMag ... low doses of siRNA.,SilenceMag formulation gives ...
... Purity is >95%NEN Radiolabeled Ligands\n\nReceptor-related research has ... of new radiolabeled ligands selected to keep ... wide range of products and services for ... 400 state-of-the-art radioligands. If you do not ...
... Test Plate consists of an anodized aluminum ... Organic Fluorescent Compounds embedded in polymerized matrix. ... BioTeks FLx800 and Synergy Multi-Detection Readers. This ... compliance while reducing the need for tedious ...
... Feature Extraction Software reads ... files to prepare microarray data ... , * one 2-year ... for NFP/Academic accounts , * ...
Biology Products: